Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC34A2 | O95436 | 3/20 | 0.35 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 5/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5740798 | 0.88 | LIMK1 (0.33) | SLC34A2S1PR1KIF11LIMK1CACNA1G | |
| SCHEMBL5740285 | 0.87 | CYP26A1 (0.40) | SLC34A2S1PR1KIF11CACNA1GCACNA1H | |
| SCHEMBL5739244 | 0.85 | L3MBTL1 (0.33) | SLC34A2KIF11LIMK1 | |
| SCHEMBL5740233 | 0.81 | LIMK1 (0.40) | KIF11LIMK1ESR1ESR2PDE4B | |
| SCHEMBL5738947 | 0.81 | LIMK1 (0.35) | KIF11LIMK1ESR1ESR2CACNA1G | |
| SCHEMBL5741839 | 0.81 | RXRA (0.37) | SLC34A2KIF11LIMK1PDE4BPDE4D | |
| SCHEMBL6508440 | 0.80 | KIF11 (0.34) | SLC34A2S1PR1KIF11PDE4BPDE4D | |
| SCHEMBL5741193 | 0.78 | POLB (0.35) | LIMK1 | |
| SCHEMBL5741841 | 0.78 | FABP4 (0.33) | SLC34A2S1PR1KIF11LIMK1PDE4B | |
| SCHEMBL5741506 | 0.78 | RAB9A (0.38) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406891-B1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2006-03-22 | — | — | EP | disclosed |
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | US | disclosed |
| EP-1406891-A1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | Bayer HealthCare AG (DE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003053955-A1 | THIOCHROMENONES USED TO COMBAT PAINFUL CONDITIONS AND NEURODEGENERATIVE DISEASES | BAYER HEALTHCARE AG (DE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009820-A1 | Thiochromenones used to combat painful conditions and neurodegenerative diseases | HTT, HMOX1, SNCA | SLC34A2 2985/4885GPR55 1502/4885S1PR1 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.